S B Kaye - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

S B Kaye

Showing results (381-390 of 411) with videos related to

Pageof 42

Sort By:

British Journal of Cancer|January 1, 1997

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009

A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcomaJ E Ang, R N Shah, M Everard, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II CommitteeP A Vasey, S B Kaye, R Morrison, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancerI Ganly, D Kirn, G Eckhardt, et al.

European Journal of Cancer (Oxford, England : 1990)|August 1, 1997

Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapyS D Fosså, R T Oliver, S P Stenning, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials GroupP A Vasey, J Paul, A Birt, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.

Pageof 42

Search research articles

Showing results (381-390 of 411) with videos related to

Sort By:

Pageof 42

British Journal of Cancer|January 1, 1997

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998

Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancerI Ganly, D Kirn, G Eckhardt, et al.

European Journal of Cancer (Oxford, England : 1990)|August 1, 1997

Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapyS D Fosså, R T Oliver, S P Stenning, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials GroupP A Vasey, J Paul, A Birt, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.

Pageof 42